Amgen recalls anemia drugs due to glass flakes

Sep 24, 2010

(AP) -- Amgen Inc. is recalling some lots of its Epogen and Procrit anemia treatments because they may contain glass flakes.

The Thousand Oaks, Calif., biotechnology company says the flakes are barely visible in most cases, and they have fielded no complaints or reports about problems that can be directly tied to them.

Amgen says the flakes are caused by the interaction of the drug with glass vials over the product's shelf life.

The affected lot numbers and expiration dates can be found on Web sites for the products.

Epogen treats in patients with chronic renal failure who are on dialysis. Procrit also treats it for on and some HIV-infected patients.

Explore further: New treatment approved for rare form of hemophilia

More information: http://www.epogen.com , http://www.procrit.com .

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Anemia drugs under scrutiny

Mar 13, 2008

U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.

Study finds stroke risk from anemia drug Aranesp

Oct 31, 2009

(AP) -- A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick ...

Patient privacy focus of Amgen suit

Jan 09, 2008

Two former employees with the California biotech company Amgen Inc. allege the company persuaded sales people to access patient records to boost sales.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

17 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0